|
US5703058A
(en)
*
|
1995-01-27 |
1997-12-30 |
Emory University |
Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
|
|
EA008609B1
(ru)
*
|
1998-02-25 |
2007-06-29 |
Эмори Юниверсити |
2'-фторнуклеозиды
|
|
MXPA02008078A
(es)
|
2000-02-18 |
2002-11-29 |
Julio Javier Cristiani |
Metodo para el tratamiento o prevencion de infecciones por flavivirus utilizando analogos de nucleosidos.
|
|
KR20100003313A
(ko)
|
2000-04-13 |
2010-01-07 |
파마셋 인코포레이티드 |
간염 바이러스 감염 치료를 위한 3'- 또는 2'-하이드록시메틸 치환된 뉴클레오시드 유도체
|
|
MY164523A
(en)
*
|
2000-05-23 |
2017-12-29 |
Univ Degli Studi Cagliari |
Methods and compositions for treating hepatitis c virus
|
|
EA200601591A1
(ru)
*
|
2000-05-26 |
2007-02-27 |
Айденикс (Кайман) Лимитед |
Применение рибонуклеозидных соединений для лечения флавивирусных и пестивирусных инфекций
|
|
FR2810319A1
(fr)
*
|
2000-06-15 |
2001-12-21 |
Ppg Sipsy |
Composes alpha-phenylsulfinyl-alpha-halogeno-butyrolactone et halogeno-2-buten-2-olide-4 utiles pour la preparation de composes halogeno-2-oxymethyl-4-furanone (4h)
|
|
US20030008841A1
(en)
*
|
2000-08-30 |
2003-01-09 |
Rene Devos |
Anti-HCV nucleoside derivatives
|
|
CA2426187C
(en)
*
|
2000-10-18 |
2011-08-16 |
Pharmasset Limited |
Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation
|
|
US7105499B2
(en)
|
2001-01-22 |
2006-09-12 |
Merck & Co., Inc. |
Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
|
|
CN1267446C
(zh)
*
|
2001-01-22 |
2006-08-02 |
默克公司 |
作为依赖于rna的rna病毒聚合酶的抑制剂的核苷衍生物
|
|
US8481712B2
(en)
|
2001-01-22 |
2013-07-09 |
Merck Sharp & Dohme Corp. |
Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
|
|
US6900315B2
(en)
|
2001-02-06 |
2005-05-31 |
Yale University |
2-amino-9H-purin-9-yl compounds and methods for inhibiting/treating HIV infections and AIDS related symptoms
|
|
EP1363927A2
(en)
|
2001-03-01 |
2003-11-26 |
Pharmasset Limited |
Method for the synthesis of 2',3'-dideoxy-2',3'-didehydronucleosides
|
|
WO2002069903A2
(en)
*
|
2001-03-06 |
2002-09-12 |
Biocryst Pharmaceuticals, Inc. |
Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases
|
|
GB0112617D0
(en)
*
|
2001-05-23 |
2001-07-18 |
Hoffmann La Roche |
Antiviral nucleoside derivatives
|
|
GB0114286D0
(en)
|
2001-06-12 |
2001-08-01 |
Hoffmann La Roche |
Nucleoside Derivatives
|
|
US6949522B2
(en)
|
2001-06-22 |
2005-09-27 |
Pharmasset, Inc. |
β-2′- or 3′-halonucleosides
|
|
US7138376B2
(en)
*
|
2001-09-28 |
2006-11-21 |
Idenix Pharmaceuticals, Inc. |
Methods and compositions for treating hepatitis C virus using 4'-modified nucleosides
|
|
US7049303B2
(en)
*
|
2001-11-07 |
2006-05-23 |
Medical Research Council |
Inhibition of viruses
|
|
WO2003063771A2
(en)
|
2001-12-14 |
2003-08-07 |
Pharmasset Ltd. |
N4-acylcytosine nucleosides for treatment of viral iinfections
|
|
MXPA04007876A
(es)
*
|
2002-02-14 |
2005-06-20 |
Pharmasset Ltd |
Analogos de nucleosido fluorado modificados.
|
|
CN101172993A
(zh)
|
2002-06-28 |
2008-05-07 |
埃迪尼克斯(开曼)有限公司 |
用于治疗黄病毒感染的2′－c－甲基－3′－o－l－缬氨酸酯核糖呋喃基胞苷
|
|
US7608600B2
(en)
*
|
2002-06-28 |
2009-10-27 |
Idenix Pharmaceuticals, Inc. |
Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
|
|
AU2003247084B9
(en)
*
|
2002-06-28 |
2018-07-26 |
Centre National De La Recherche Scientifique |
Modified 2' and 3'-nucleoside prodrugs for treating flaviridae infections
|
|
CA2489552A1
(en)
|
2002-06-28 |
2004-01-08 |
Idenix (Cayman) Limited |
2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
|
|
US20040067877A1
(en)
|
2002-08-01 |
2004-04-08 |
Schinazi Raymond F. |
2', 3'-Dideoxynucleoside analogues for the treatment or prevention of Flaviviridae infections
|
|
US8093380B2
(en)
|
2002-08-01 |
2012-01-10 |
Pharmasset, Inc. |
Compounds with the bicyclo[4.2.1]nonane system for the treatment of Flaviviridae infections
|
|
US6884880B2
(en)
*
|
2002-08-21 |
2005-04-26 |
Ash Stevens, Inc. |
Process for the preparation of 9-β-anomeric nucleoside analogs
|
|
US7902203B2
(en)
*
|
2002-11-01 |
2011-03-08 |
Abbott Laboratories, Inc. |
Anti-infective agents
|
|
ES2624353T3
(es)
*
|
2002-11-15 |
2017-07-13 |
Idenix Pharmaceuticals Llc |
2'-Metil nucleósidos en combinación con interferón y mutación de Flaviviridae
|
|
MXPA05006230A
(es)
*
|
2002-12-12 |
2005-09-20 |
Idenix Cayman Ltd |
Proceso para la produccion de nucleosidos ramificados-2'.
|
|
NZ540913A
(en)
*
|
2002-12-23 |
2008-02-29 |
Idenix Cayman Ltd |
Process for the production of 3'-nucleoside prodrugs
|
|
CA2529311A1
(en)
*
|
2003-03-28 |
2004-10-07 |
Pharmasset, Inc. |
Compounds for the treatment of flaviviridae infections
|
|
US7595390B2
(en)
*
|
2003-04-28 |
2009-09-29 |
Novartis Ag |
Industrially scalable nucleoside synthesis
|
|
HUE029877T2
(en)
|
2003-05-30 |
2017-04-28 |
Gilead Pharmasset Llc |
Modified fluorinated nucleoside analogues
|
|
WO2005003374A2
(en)
|
2003-06-30 |
2005-01-13 |
Idenix (Cayman) Limited |
SYNTHESIS OF β-L-2-DEOXY NUCLEOSIDES
|
|
JP2007501185A
(ja)
*
|
2003-07-25 |
2007-01-25 |
イデニクス（ケイマン）リミテツド |
Ｃ型肝炎を含むフラビウイルス関連疾患を治療するためのプリンヌクレオシド類似体
|
|
WO2005018330A1
(en)
*
|
2003-08-18 |
2005-03-03 |
Pharmasset, Inc. |
Dosing regimen for flaviviridae therapy
|
|
NZ546055A
(en)
|
2003-08-27 |
2010-05-28 |
Biota Scient Management |
Novel tricyclic nucleosides or nucleotides as therapeutic agents
|
|
EP1668023A1
(de)
*
|
2003-09-12 |
2006-06-14 |
Max-Delbrück-Centrum Für Molekulare Medizin |
B-l-nucleoside und ihre verwendung als pharmazeutische mittel zur behandlung viraler erkrankungen
|
|
GB0500020D0
(en)
|
2005-01-04 |
2005-02-09 |
Novartis Ag |
Organic compounds
|
|
US20050182252A1
(en)
|
2004-02-13 |
2005-08-18 |
Reddy K. R. |
Novel 2'-C-methyl nucleoside derivatives
|
|
KR100839394B1
(ko)
*
|
2004-06-09 |
2008-06-20 |
에프. 호프만-라 로슈 아게 |
피라졸로 피리미딘
|
|
US7405220B2
(en)
*
|
2004-06-09 |
2008-07-29 |
Hoffmann-La Roche Inc. |
Pyrazolopyrimidines
|
|
AU2005254057B2
(en)
|
2004-06-15 |
2011-02-17 |
Isis Pharmaceuticals, Inc. |
C-purine nucleoside analogs as inhibitors of RNA-dependent RNA viral polymerase
|
|
EP1912643A2
(en)
*
|
2004-06-23 |
2008-04-23 |
Idenix (Cayman) Limited |
5-aza-7-deazapurine derivatives for treating infections with flaviviridae
|
|
CA2571079A1
(en)
|
2004-06-24 |
2006-02-02 |
Merck & Co., Inc. |
Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
|
|
CN101023094B
(zh)
*
|
2004-07-21 |
2011-05-18 |
法莫赛特股份有限公司 |
烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
|
|
CN101044151B
(zh)
*
|
2004-08-23 |
2011-01-19 |
弗·哈夫曼-拉罗切有限公司 |
抗病毒的4＇-叠氮基-核苷
|
|
PL3109244T3
(pl)
*
|
2004-09-14 |
2019-09-30 |
Gilead Pharmasset Llc |
Wytwarzanie 2'fluoro-2'-alkilo-podstawionych lub innych ewentualnie podstawionych rybofuranozylopirymidyn i puryn oraz ich pochodnych
|
|
WO2006093801A1
(en)
*
|
2005-02-25 |
2006-09-08 |
Abbott Laboratories |
Thiadiazine derivatives useful as anti-infective agents
|
|
US7524831B2
(en)
|
2005-03-02 |
2009-04-28 |
Schering Corporation |
Treatments for Flaviviridae virus infection
|
|
CA2600886A1
(en)
|
2005-03-08 |
2006-09-14 |
Biota Scientific Management Pty Ltd. |
Bicyclic nucleosides and nucleotides as therapeutic agents
|
|
JP4516863B2
(ja)
*
|
2005-03-11 |
2010-08-04 |
株式会社ケンウッド |
音声合成装置、音声合成方法及びプログラム
|
|
AU2006242475B2
(en)
|
2005-05-02 |
2011-07-07 |
Merck Sharp & Dohme Corp. |
HCV NS3 protease inhibitors
|
|
US7470664B2
(en)
|
2005-07-20 |
2008-12-30 |
Merck & Co., Inc. |
HCV NS3 protease inhibitors
|
|
JP4705984B2
(ja)
|
2005-08-01 |
2011-06-22 |
メルク・シャープ・エンド・ドーム・コーポレイション |
Ｈｃｖｎｓ３プロテアーゼ阻害剤としての大環状ペプチド
|
|
US7705009B2
(en)
*
|
2005-11-22 |
2010-04-27 |
Hoffman-La Roche Inc. |
4-aminopyrimidine-5-thione derivatives
|
|
WO2007065829A1
(en)
*
|
2005-12-09 |
2007-06-14 |
F. Hoffmann-La Roche Ag |
Antiviral nucleosides
|
|
EP2345652A1
(en)
|
2005-12-21 |
2011-07-20 |
Abbott Laboratories |
Antiviral compounds
|
|
ATE475660T1
(de)
*
|
2005-12-21 |
2010-08-15 |
Abbott Lab |
Antivirale verbindungen
|
|
CN102702193A
(zh)
*
|
2005-12-21 |
2012-10-03 |
雅培制药有限公司 |
抗病毒化合物
|
|
WO2007081517A2
(en)
|
2005-12-21 |
2007-07-19 |
Abbott Laboratories |
Anti-viral compounds
|
|
ES2422290T3
(es)
*
|
2005-12-23 |
2013-09-10 |
Idenix Pharmaceuticals Inc |
Procedimiento para preparar un producto intermedio sintético para la preparación de nucleósidos ramificados
|
|
KR101237312B1
(ko)
*
|
2006-02-10 |
2013-03-04 |
삼진제약주식회사 |
피리미딘다이온 유도체를 포함하는 ｃ형 간염의 예방 및치료용 약학 조성물
|
|
US8895531B2
(en)
|
2006-03-23 |
2014-11-25 |
Rfs Pharma Llc |
2′-fluoronucleoside phosphonates as antiviral agents
|
|
WO2010005847A1
(en)
*
|
2008-07-08 |
2010-01-14 |
The Regents Of The University Of California |
Acid-degradable and bioerodible modified polyhydroxylated materials
|
|
US9644039B2
(en)
|
2006-03-24 |
2017-05-09 |
The Regents Of The University Of California |
Acid-degradable and bioerodible modified polyhydroxylated materials
|
|
KR101059593B1
(ko)
|
2006-04-11 |
2011-08-25 |
노파르티스 아게 |
Ｈｃｖ/ｈｉｖ 억제제 및 이들의 용도
|
|
GB0609492D0
(en)
|
2006-05-15 |
2006-06-21 |
Angeletti P Ist Richerche Bio |
Therapeutic agents
|
|
GB0612423D0
(en)
|
2006-06-23 |
2006-08-02 |
Angeletti P Ist Richerche Bio |
Therapeutic agents
|
|
WO2008011337A1
(en)
*
|
2006-07-19 |
2008-01-24 |
Abbott Laboratories |
Hcv inhibitors
|
|
US20090298708A1
(en)
*
|
2006-08-23 |
2009-12-03 |
Masad Damha J |
2'-deoxy-2'-fluoro-beta-d-arabinonucleoside 5'-triphosphates and their use in enzymatic nucleic acid synthesis
|
|
ES2358853T3
(es)
*
|
2006-10-10 |
2011-05-16 |
Medivir Ab |
Inhibidor nucleosídico de vhc.
|
|
KR101057239B1
(ko)
*
|
2006-10-10 |
2011-08-16 |
에프. 호프만-라 로슈 아게 |
뉴클레오사이드 리보푸라노실 피리미딘의 제조
|
|
CN101583372A
(zh)
|
2006-10-24 |
2009-11-18 |
默克公司 |
Hcv ns3蛋白酶抑制剂
|
|
AU2007309546A1
(en)
|
2006-10-24 |
2008-05-02 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. |
HCV NS3 protease inhibitors
|
|
US8138164B2
(en)
|
2006-10-24 |
2012-03-20 |
Merck Sharp & Dohme Corp. |
HCV NS3 protease inhibitors
|
|
CA2667032A1
(en)
|
2006-10-27 |
2008-05-15 |
Merck & Co., Inc. |
Hcv ns3 protease inhibitors
|
|
EP2086982B1
(en)
|
2006-10-27 |
2018-08-29 |
Merck Sharp & Dohme Corp. |
Hcv ns3 protease inhibitors
|
|
WO2008075103A1
(en)
|
2006-12-20 |
2008-06-26 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa |
Antiviral indoles
|
|
WO2008133753A2
(en)
*
|
2006-12-20 |
2008-11-06 |
Abbott Laboratories |
Anti-viral compounds
|
|
GB0625349D0
(en)
|
2006-12-20 |
2007-01-31 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
|
GB0625345D0
(en)
|
2006-12-20 |
2007-01-31 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
|
US7951789B2
(en)
|
2006-12-28 |
2011-05-31 |
Idenix Pharmaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
|
AU2007342367B2
(en)
|
2007-01-05 |
2012-12-06 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. |
Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection
|
|
WO2008106166A2
(en)
|
2007-02-28 |
2008-09-04 |
Conatus Pharmaceuticals, Inc. |
Methods for the treatment of liver diseases using specified matrix metalloproteinase (mmp) inhibitors
|
|
BRPI0809123A2
(pt)
*
|
2007-03-23 |
2016-07-26 |
Southern Res Inst |
método de tratamento ou prevenção da artrite
|
|
US7964580B2
(en)
|
2007-03-30 |
2011-06-21 |
Pharmasset, Inc. |
Nucleoside phosphoramidate prodrugs
|
|
CN100532388C
(zh)
|
2007-07-16 |
2009-08-26 |
郑州大学 |
2’-氟-4’-取代-核苷类似物、其制备方法及应用
|
|
WO2009010785A1
(en)
|
2007-07-17 |
2009-01-22 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa |
Macrocyclic indole derivatives for the treatment of hepatitis c infections
|
|
US8927569B2
(en)
|
2007-07-19 |
2015-01-06 |
Merck Sharp & Dohme Corp. |
Macrocyclic compounds as antiviral agents
|
|
WO2009058800A2
(en)
*
|
2007-10-29 |
2009-05-07 |
President And Fellows Of Harvard College |
Synthesis of nucleosides
|
|
TW200946541A
(en)
|
2008-03-27 |
2009-11-16 |
Idenix Pharmaceuticals Inc |
Solid forms of an anti-HIV phosphoindole compound
|
|
CN102014911A
(zh)
|
2008-04-28 |
2011-04-13 |
默沙东公司 |
Hcv ns3蛋白酶抑制剂
|
|
US20090274686A1
(en)
*
|
2008-05-02 |
2009-11-05 |
Yat Sun Or |
Nucleoside phosphonate derivatives
|
|
US8173621B2
(en)
|
2008-06-11 |
2012-05-08 |
Gilead Pharmasset Llc |
Nucleoside cyclicphosphates
|
|
BRPI0913677A2
(pt)
|
2008-07-02 |
2015-12-15 |
Idenix Pharmaceuticals Inc |
composto, metabólito purificado, método para tratar um hospedeiro infectado com um vírus flaviviridade, composição farmacêutica, método para preparar o composto purificado, e, processo para preparar o composto
|
|
WO2010002877A2
(en)
|
2008-07-03 |
2010-01-07 |
Biota Scientific Management |
Bycyclic nucleosides and nucleotides as therapeutic agents
|
|
EP2310095B1
(en)
|
2008-07-22 |
2012-08-29 |
Merck Sharp & Dohme Corp. |
Macrocyclic quinoxaline compounds as hcv ns3 protease inhibitors
|
|
PA8855801A1
(es)
*
|
2008-12-23 |
2010-07-27 |
|
Sintesis de nucleosidos de purina
|
|
SG172359A1
(en)
|
2008-12-23 |
2011-07-28 |
Pharmasset Inc |
Nucleoside phosphoramidates
|
|
AR074882A1
(es)
|
2008-12-23 |
2011-02-16 |
Pharmasset Inc |
Analogos de nucleosidos
|
|
WO2010082050A1
(en)
|
2009-01-16 |
2010-07-22 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. |
Macrocyclic and 7-aminoalkyl-substituted benzoxazocines for treatment of hepatitis c infections
|
|
GB0900914D0
(en)
|
2009-01-20 |
2009-03-04 |
Angeletti P Ist Richerche Bio |
Antiviral agents
|
|
EP2403860B1
(en)
|
2009-03-04 |
2015-11-04 |
IDENIX Pharmaceuticals, Inc. |
Phosphothiophene and phosphothiazole as hcv polymerase inhibitors
|
|
US8512690B2
(en)
|
2009-04-10 |
2013-08-20 |
Novartis Ag |
Derivatised proline containing peptide compounds as protease inhibitors
|
|
US20110182850A1
(en)
|
2009-04-10 |
2011-07-28 |
Trixi Brandl |
Organic compounds and their uses
|
|
AU2010249119A1
(en)
*
|
2009-05-12 |
2011-12-01 |
Southern Research Institute |
2'-fluoro arabino nucleosides and use thereof
|
|
MX2011012155A
(es)
|
2009-05-13 |
2012-02-28 |
Enanta Pharm Inc |
Compuestos macrociclicos como inhibidores del virus de hepatitis c.
|
|
TWI598358B
(zh)
|
2009-05-20 |
2017-09-11 |
基利法瑪席特有限責任公司 |
核苷磷醯胺
|
|
US8618076B2
(en)
|
2009-05-20 |
2013-12-31 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
|
US8828930B2
(en)
|
2009-07-30 |
2014-09-09 |
Merck Sharp & Dohme Corp. |
Hepatitis C virus NS3 protease inhibitors
|
|
WO2011014882A1
(en)
|
2009-07-31 |
2011-02-03 |
Medtronic, Inc. |
CONTINUOUS SUBCUTANEOUS ADMINISTRATION OF INTERFERON-α TO HEPATITIS C INFECTED PATIENTS
|
|
AR077712A1
(es)
|
2009-08-05 |
2011-09-14 |
Idenix Pharmaceuticals Inc |
Inhibidores de serina proteasa macrociclica
|
|
CA2780044A1
(en)
|
2009-11-14 |
2011-05-19 |
F. Hoffmann-La Roche Ag |
Biomarkers for predicting rapid response to hcv treatment
|
|
US8816074B2
(en)
*
|
2009-11-16 |
2014-08-26 |
University of Georgia Foundation, Inc. |
2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections
|
|
US9700560B2
(en)
|
2009-11-16 |
2017-07-11 |
University Of Georgia Research Foundation, Inc. |
2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections
|
|
US20110117055A1
(en)
|
2009-11-19 |
2011-05-19 |
Macdonald James E |
Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds
|
|
BR112012011393A2
(pt)
|
2009-12-02 |
2017-06-20 |
Hoffmann La Roche |
biomarcadores para a previsão da resposta sustentada ao tratamento de hcv
|
|
BR112012014899A2
(pt)
|
2009-12-18 |
2017-03-14 |
Idenix Pharmaceuticals Inc |
composto, composição farmacêutica, método para tratar ou prevenir uma infecção por vírus de hepatite c em um sujeito, método para tratar , prevenir ou melhorar um ou mais sintomas de uma doença hepática ou distúrbio associado a uma infecção por vírus de hepatite c em um sujeito, método para inibir a replicação de um vírus em um hospedeiro, método para inibir a replicação de um vírus
|
|
PL3290428T3
(pl)
|
2010-03-31 |
2022-02-07 |
Gilead Pharmasset Llc |
Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
|
|
ES2516466T3
(es)
|
2010-03-31 |
2014-10-30 |
Gilead Pharmasset Llc |
Síntesis estereoselectiva de agentes activos que contienen fósforo
|
|
CA2795054A1
(en)
|
2010-04-01 |
2011-10-06 |
Idenix Pharmaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
|
US9284188B2
(en)
|
2010-09-03 |
2016-03-15 |
The Regents Of The University Of California |
Cytosolic delivery of materials with endosome-disrupting colloids
|
|
SG188618A1
(en)
|
2010-09-21 |
2013-04-30 |
Enanta Pharm Inc |
Macrocyclic proline derived hcv serine protease inhibitors
|
|
CN103179966B
(zh)
|
2010-10-08 |
2017-03-15 |
诺瓦提斯公司 |
磺酰胺ns3抑制剂的维生素e制剂
|
|
EP2646453A1
(en)
|
2010-11-30 |
2013-10-09 |
Gilead Pharmasset LLC |
Compounds
|
|
WO2012080050A1
(en)
|
2010-12-14 |
2012-06-21 |
F. Hoffmann-La Roche Ag |
Solid forms of a phenoxybenzenesulfonyl compound
|
|
WO2012109398A1
(en)
|
2011-02-10 |
2012-08-16 |
Idenix Pharmaceuticals, Inc. |
Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating hcv infections
|
|
US20120252721A1
(en)
|
2011-03-31 |
2012-10-04 |
Idenix Pharmaceuticals, Inc. |
Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
|
|
JP2014514295A
(ja)
|
2011-03-31 |
2014-06-19 |
アイディニックス ファーマシューティカルズ インコーポレイテッド |
ウイルス感染の治療のための化合物および薬学的組成物
|
|
CN103582420B
(zh)
|
2011-04-13 |
2016-10-19 |
默沙东公司 |
2’-取代的核苷衍生物和使用其治疗病毒病的方法
|
|
WO2012142093A2
(en)
|
2011-04-13 |
2012-10-18 |
Merck Sharp & Dohme Corp. |
2'-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
|
|
US9156872B2
(en)
|
2011-04-13 |
2015-10-13 |
Merck Sharp & Dohme Corp. |
2′-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
|
|
WO2013009737A1
(en)
|
2011-07-13 |
2013-01-17 |
Merck Sharp & Dohme Corp. |
5'-substituted nucleoside analogs and methods of use thereof for the treatment of viral diseases
|
|
WO2013009735A1
(en)
|
2011-07-13 |
2013-01-17 |
Merck Sharp & Dohme Corp. |
5'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
|
|
WO2013039855A1
(en)
|
2011-09-12 |
2013-03-21 |
Idenix Pharmaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
|
WO2013039920A1
(en)
|
2011-09-12 |
2013-03-21 |
Idenix Pharmaceuticals, Inc. |
Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
|
|
PH12014500557A1
(en)
|
2011-09-16 |
2014-05-26 |
Gilead Pharmasset Llc |
Methods for treating hcv
|
|
EP2768838A1
(en)
|
2011-10-14 |
2014-08-27 |
IDENIX Pharmaceuticals, Inc. |
Substituted 3',5'-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
|
|
EP2776438A4
(en)
*
|
2011-11-10 |
2015-04-29 |
Inhibitex Inc |
SUBSTITUTED PURIN NUCLEOSIDES, PHOSPHORAMIDATE AND PHOSPHORDIAMIDATE DERIVATIVES FOR THE TREATMENT OF VIRUS INFECTIONS
|
|
US9328138B2
(en)
|
2011-11-15 |
2016-05-03 |
Msd Italia S.R.L. |
HCV NS3 protease inhibitors
|
|
US8889159B2
(en)
|
2011-11-29 |
2014-11-18 |
Gilead Pharmasset Llc |
Compositions and methods for treating hepatitis C virus
|
|
CN104185420B
(zh)
|
2011-11-30 |
2017-06-09 |
埃默里大学 |
用于治疗或预防逆转录病毒和其它病毒感染的抗病毒jak抑制剂
|
|
WO2013106344A1
(en)
|
2012-01-12 |
2013-07-18 |
Ligand Pharmaceuticals, Inc. |
2 '-c-methyl nucleosides containing a cyclic phosphate diester of 1, 3-propanediol (2-oxo-[1, 3, 2]-dioxaphosphorinane) at position 5'
|
|
WO2013133927A1
(en)
|
2012-02-13 |
2013-09-12 |
Idenix Pharmaceuticals, Inc. |
Pharmaceutical compositions of 2'-c-methyl-guanosine, 5'-[2-[(3-hydroxy-2,2-dimethyl-1-oxopropyl)thio]ethyl n-(phenylmethyl)phosphoramidate]
|
|
EA201491525A1
(ru)
|
2012-02-14 |
2014-12-30 |
Юниверсити Оф Джорджиа Рисерч Фаундэйшн, Инк. |
Спиро[2.4]гептаны для лечения инфекций, вызванных flaviviridae
|
|
EP2852604B1
(en)
|
2012-05-22 |
2017-04-12 |
Idenix Pharmaceuticals LLC |
3',5'-cyclic phosphoramidate prodrugs for hcv infection
|
|
HK1203514A1
(en)
|
2012-05-22 |
2015-10-30 |
Idenix Pharmaceuticals Llc |
D-amino acid compounds for liver disease
|
|
WO2013177195A1
(en)
|
2012-05-22 |
2013-11-28 |
Idenix Pharmaceuticals, Inc. |
3',5'-cyclic phosphate prodrugs for hcv infection
|
|
HUE029038T2
(en)
|
2012-05-25 |
2017-01-30 |
Janssen Sciences Ireland Uc |
Uracil spirooxetan nucleosides
|
|
WO2014052638A1
(en)
|
2012-09-27 |
2014-04-03 |
Idenix Pharmaceuticals, Inc. |
Esters and malonates of sate prodrugs
|
|
EP2900684A2
(en)
|
2012-09-29 |
2015-08-05 |
Novartis AG |
Cyclic peptides and use as medicines
|
|
MX353422B
(es)
|
2012-10-08 |
2018-01-12 |
Idenix Pharmaceuticals Llc |
Análogos de 2'-cloronucleósido para infección por vhc.
|
|
US20140112886A1
(en)
|
2012-10-19 |
2014-04-24 |
Idenix Pharmaceuticals, Inc. |
Dinucleotide compounds for hcv infection
|
|
WO2014066239A1
(en)
|
2012-10-22 |
2014-05-01 |
Idenix Pharmaceuticals, Inc. |
2',4'-bridged nucleosides for hcv infection
|
|
WO2014078427A1
(en)
|
2012-11-14 |
2014-05-22 |
Idenix Pharmaceuticals, Inc. |
D-alanine ester of rp-nucleoside analog
|
|
WO2014078436A1
(en)
|
2012-11-14 |
2014-05-22 |
Idenix Pharmaceuticals, Inc. |
D-alanine ester of sp-nucleoside analog
|
|
WO2014099941A1
(en)
|
2012-12-19 |
2014-06-26 |
Idenix Pharmaceuticals, Inc. |
4'-fluoro nucleosides for the treatment of hcv
|
|
GEP201706757B
(en)
|
2012-12-21 |
2017-10-25 |
Alios Biopharma Inc |
Substituted nucleosides, nucleotides and analogs thereof
|
|
SG11201506021XA
(en)
|
2013-01-31 |
2015-08-28 |
Gilead Pharmasset Llc |
Combination formulation of two antiviral compounds
|
|
WO2014121417A1
(en)
|
2013-02-07 |
2014-08-14 |
Merck Sharp & Dohme Corp. |
Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
|
|
WO2014121418A1
(en)
|
2013-02-07 |
2014-08-14 |
Merck Sharp & Dohme Corp. |
Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
|
|
WO2014137926A1
(en)
|
2013-03-04 |
2014-09-12 |
Idenix Pharmaceuticals, Inc. |
3'-deoxy nucleosides for the treatment of hcv
|
|
WO2014137930A1
(en)
|
2013-03-04 |
2014-09-12 |
Idenix Pharmaceuticals, Inc. |
Thiophosphate nucleosides for the treatment of hcv
|
|
EP2970357B1
(en)
|
2013-03-13 |
2025-01-01 |
Idenix Pharmaceuticals LLC |
Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
|
|
RU2534613C2
(ru)
|
2013-03-22 |
2014-11-27 |
Александр Васильевич Иващенко |
Алкил 2-{ [(2r,3s,5r)-5-(4-амино-2-оксо-2н-пиримидин-1-ил)- -гидрокси-тетрагидро-фуран-2-илметокси]-фенокси-фосфориламино} -пропионаты, нуклеозидные ингибиторы рнк-полимеразы hcv ns5b, способы их получения и применения
|
|
US9187515B2
(en)
|
2013-04-01 |
2015-11-17 |
Idenix Pharmaceuticals Llc |
2′,4′-fluoro nucleosides for the treatment of HCV
|
|
WO2014197578A1
(en)
|
2013-06-05 |
2014-12-11 |
Idenix Pharmaceuticals, Inc. |
1',4'-thio nucleosides for the treatment of hcv
|
|
WO2015017713A1
(en)
|
2013-08-01 |
2015-02-05 |
Idenix Pharmaceuticals, Inc. |
D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
|
|
EP3038601B1
(en)
|
2013-08-27 |
2020-04-08 |
Gilead Pharmasset LLC |
Combination formulation of two antiviral compounds
|
|
US20160229866A1
(en)
|
2013-09-20 |
2016-08-11 |
Idenix Pharmaceuticals Inc. |
Hepatitis c virus inhibitors
|
|
WO2015061683A1
(en)
|
2013-10-25 |
2015-04-30 |
Idenix Pharmaceuticals, Inc. |
D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv
|
|
WO2015066341A2
(en)
|
2013-10-30 |
2015-05-07 |
Green Life Biotech, Llc |
Pathogenesis quantification systems and treatment methods for citrus greening blight
|
|
WO2015066370A1
(en)
|
2013-11-01 |
2015-05-07 |
Idenix Pharmaceuticals, Inc. |
D-alanine phosphoramidate pronucleotides of 2'-methyl 2'-fluoro guanosine nucleoside compounds for the treatment of hcv
|
|
US20170198005A1
(en)
|
2013-11-27 |
2017-07-13 |
Idenix Pharmaceuticals Llc |
2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
|
|
WO2015095419A1
(en)
|
2013-12-18 |
2015-06-25 |
Idenix Pharmaceuticals, Inc. |
4'-or nucleosides for the treatment of hcv
|
|
US10449210B2
(en)
|
2014-02-13 |
2019-10-22 |
Ligand Pharmaceuticals Inc. |
Prodrug compounds and their uses
|
|
WO2015134560A1
(en)
|
2014-03-05 |
2015-09-11 |
Idenix Pharmaceuticals, Inc. |
Solid forms of a flaviviridae virus inhibitor compound and salts thereof
|
|
US20170135990A1
(en)
|
2014-03-05 |
2017-05-18 |
Idenix Pharmaceuticals Llc |
Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection
|
|
EP3131914B1
(en)
|
2014-04-16 |
2023-05-10 |
Idenix Pharmaceuticals LLC |
3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
|
|
US9994600B2
(en)
|
2014-07-02 |
2018-06-12 |
Ligand Pharmaceuticals, Inc. |
Prodrug compounds and uses therof
|
|
MX2017011386A
(es)
|
2015-03-06 |
2018-04-26 |
Atea Pharmaceuticals Inc |
NUCLEÓTIDOS DE PURINA ß-D-2'-DEOXI-2'A-FLUORO-2'-ß-C-SUSTITUIDOS-2 - MODIFICADOS-N6- SUSTITUIDOS PARA EL TRATAMIENTO DEL VIRUS DE LA HEPATITIS C.
|
|
CN108350016B
(zh)
*
|
2015-09-02 |
2021-07-27 |
艾伯维公司 |
抗病毒四氢呋喃衍生物
|
|
US10202412B2
(en)
|
2016-07-08 |
2019-02-12 |
Atea Pharmaceuticals, Inc. |
β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections
|
|
WO2018013937A1
(en)
|
2016-07-14 |
2018-01-18 |
Atea Pharmaceuticals, Inc. |
Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
|
|
RS62943B1
(sr)
|
2016-09-07 |
2022-03-31 |
Atea Pharmaceuticals Inc |
2’-supstituisani-n6-supstituisani purinski nukleotidi za lečenje bolesti izazvanih rnk virusima
|
|
US11234454B2
(en)
|
2016-12-15 |
2022-02-01 |
Société des Produits Nestlé S.A. |
Compositions and methods that modulate cholesterol in a companion animal
|
|
EP3554258B1
(en)
|
2016-12-15 |
2023-07-19 |
Société des Produits Nestlé S.A. |
Compositions and methods that modulate phosphorus or enzymes in a companion animal
|
|
IL288737B
(en)
|
2017-02-01 |
2022-09-01 |
Atea Pharmaceuticals Inc |
Hemisulfate nucleotide salt for treatment of hepatitis c virus
|
|
US10851125B2
(en)
|
2017-08-01 |
2020-12-01 |
Gilead Sciences, Inc. |
Crystalline forms of ethyl ((S)-((((2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl(-L-alaninate
|
|
RU2020126177A
(ru)
|
2018-01-09 |
2022-02-10 |
Лиганд Фармасьютикалз, Инк. |
Ацетальные соединения и их терапевтическое применение
|
|
TW202012001A
(zh)
|
2018-04-10 |
2020-04-01 |
美商亞堤製藥公司 |
C型肝炎病毒(hcv)感染硬化之患者的治療
|
|
WO2020045628A1
(ja)
*
|
2018-08-31 |
2020-03-05 |
ダイキン工業株式会社 |
核酸アナログ及び抗ｂ型肝炎ウイルス剤
|
|
EP3891508A1
(en)
|
2018-12-04 |
2021-10-13 |
Bristol-Myers Squibb Company |
Methods of analysis using in-sample calibration curve by multiple isotopologue reaction monitoring
|
|
US10874687B1
(en)
|
2020-02-27 |
2020-12-29 |
Atea Pharmaceuticals, Inc. |
Highly active compounds against COVID-19
|
|
US20240261317A1
(en)
*
|
2021-05-17 |
2024-08-08 |
Rome Therapeutics, Inc. |
Methods of treating medical conditions and inhibiting line1 reverse transcriptaseusing a substituted 4-fluoro-2,5-dihydrofuranyl phosphonic acid or related compound
|
|
JP2024525164A
(ja)
|
2021-06-17 |
2024-07-10 |
アテア ファーマシューティカルズ， インコーポレイテッド |
有利な抗ｈｃｖ併用療法
|